#156374

Anti-ABeta (Abeta) [6C3]

Cat. #156374

Anti-ABeta (Abeta) [6C3]

Cat. #: 156374

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Amyloid-? Peptide

Class: Monoclonal

Application: IHC ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: University of Illinois Chicago

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-ABeta (Abeta) [6C3]
  • Alternate name: AÎ? or Abeta
  • Research fields: Apoptosis and autophagy;Cell biology;Developmental biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; WB
  • Description: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.
  • Immunogen: Human beta Amyloid. Recombinant oligomeric A?42. Epitope maps to residues 1-4 of human A?42 and A?40 (DAEF).
  • Recommended controls: IgG2b

Target Details

  • Target: Amyloid-? Peptide
  • Tissue cell line specificity: IgG2b
  • Target background: Defects in APP are associated with the pathology of various types of Alzheimer's disease. Specially, the defective amyloid-beta-APP 40-42 peptides, which MOAB-2 targets exclusively, are major constituents of extracellular plaques and contribute cytotoxic neuronal death.

Applications

  • Application: IHC ; WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Shipping at 4° C

References

  • 295587871
  • Fekete et al. 2019. Neuroscience. 405:35-46. PMID: 29522854.
  • Scaringi et al. 2012. Anticancer Res. 32(10):4213-23. PMID: 23060541.
  • Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.
  • Youmans et al. 2012. Mol Neurodegener. 7:8. PMID: 22423893.